A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might more effectively...
Myeloma NZ
COVID-19’s Impact on How Patients with CLL, Myeloma Have Received Treatment
CURE® recently invited patients, survivors, caregivers, advocates and health care professionals to attend its first-ever live webinar, “Hear from...
Newsletter: Autumn 2020
Hello Everybody I hope that you are all coping with the lock-down as best that you can. It’s been a difficult time for many people and especially...
Blood cancer patients at most risk from COVID-19 compared to other cancers
Patients with haematological cancers are at higher risk of COVID-19 infection and experience more severe disease compared to people with other...
Spain Reviewing Trial to Treat COVID-19 Pneumonia With Myeloma Therapy Aplidin
Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its...
Genetic Test Could Determine Patients With Ultra High Risk Multiple Myeloma
A new study published in Leukemia revealed that researchers at the Institute of Cancer Research in London have found a new genetic test that could...
First case of COVID-19 in a patient with multiple myeloma
The immunosuppressant tocilizumab may be a promising option for myeloma patients with COVID-19, a case study from China suggests. Dr Changcheng...
Genetic Test Identifies Ultra-High-Risk Myeloma Patients
A new test can identify patients with multiple myeloma (MM) who have a high-risk genetic profile as well as multiple chromosomal abnormalities. In...
WEBINAR: Leading experts to give their views on treating multiple myeloma patients during the COVID-19 pandemic
The COVID-19 pandemic continues to put a strain on healthcare delivery around the world. In this environment, haematologists are adapting their...
First Report of MM Patient Successfully Treated for COVID-19 With Tocilizumab
Recent research has shown that severe cases of COVID-19 show an excessive immune response and a strong cytokine storm, which may include high levels...
Ygalo Shows Positive Response in Triple-refractory Multiple Myeloma Trial
Topline results show a 26% response rate in a Phase 2 clinical trial evaluating Ygalo (melflufen) in patients with triple-refractory multiple...
The squeeze on healthcare in locked-down New Zealand
Medical centres across the country are condensing services, moving online and ushering in pandemic plans. Josie Adams assesses what it’s like to...